We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Integrated Genomic Study Uncovers Mutations Linked to Lung Cancer

By LabMedica International staff writers
Posted on 04 Nov 2008
Cancer researchers have integrated DNA sequencing, gene expression, and DNA copy number data in a large-scale genomic study of lung adenocarcinoma that calls attention to several important signaling pathways and suggests new molecular targets for treatment.

Investigators at Harvard University (Cambridge, MA, USA) were members of a large team that participated in a pilot project (the Tumor Sequencing Project or TSP) that investigated how various genomic technologies could be effectively applied and integrated to reveal the molecular underpinnings of lung adenocarcinoma. More...
The report, which appeared in the October 23, 2008, online edition of the journal Nature, presented data obtained from studying 188 primary lung adenocarcinoma samples.

DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Analysis identified 26 genes that were mutated at significantly high frequencies and thus were probably involved in carcinogenesis. While some of these mutations were in genes already linked to lung adenocarcinoma, a substantial number were previously unrecognized. For example, the NF1, ATM, RB1, and APC genes, which had not before been associated with lung cancer, were mutated in a significant portion of the lung tumors analyzed. Mutations were also found that clustered in several groups of related tyrosine kinase genes, including the EGF, EPH, FGF, NTRK, and VEGF receptor gene families. Several of the mutated genes were tumor suppressors that already had been found to be involved in other cancers.

"DNA copy number analysis and gene expression analysis respectively, together with advanced computational methods, helped provide a detailed view of the genomic landscape of lung cancer,” explained contributing author Dr. Matthew Myerson, professor of oncology at Harvard University. "Integrative approaches like these allow us to more clearly pinpoint important genes than a single method alone would. One of the key findings from our study is that some of the newly discovered genes and pathways that are mutated in lung cancer are also known to be defective in other cancers. That gives us hope that targeted therapies could be used across multiple cancer types.”

Related Links:
Harvard University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.